|
|
Poly-ϵ-caprolactone and chitosan nanoparticles |
|
Vaxjo ID |
329 |
|
Vaccine Adjuvant Name |
Poly-ϵ-caprolactone and chitosan nanoparticles |
|
Adjuvant VO ID |
VO_0005686
|
|
Description |
Poly-ϵ-caprolactone and chitosan nanoparticles (NPs) investigated for their adjuvant effect for hepatitis B surface antigen (HBsAg) and the plasmid DNA encoding HBsAg (pRC/CMV-HBs). They provide a strong humoral adjuvant effect and induce Th1/Th17-mediated cellular immune responses. |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
poly-?-caprolactone/chitosan nanoparticles (NPs) for hepatitis B surface antigen (HBsAg) and the plasmid DNA encoding HBsAg (pRC/CMV-HBs) |
|
Structure |
Nanoparticles |
|
Function |
Poly-?-caprolactone/chitosan NPs provide a strong humoral adjuvant effect for HBsAg and induce a Th1/Th17-mediated cellular immune responses worth explore for hepatitis B virus vaccination Activates TLR3 and MDA5, and stimulates immune response. [PMC9927404] |
| References |
Jesus et al., 2017: Jesus S, Soares E, Borchard G, Borges O. Poly-ϵ-caprolactone/chitosan nanoparticles provide strong adjuvant effect for hepatitis B antigen. Nanomedicine (London, England). 2017; 12(19); 2335-2348. [PubMed: 28868964].
Panigaj et al., 2023: Panigaj M, Skelly E, Beasock D, Marriott I, Johnson MB, Salotti J, Afonin KA. Therapeutic immunomodulation by rationally designed nucleic acids and nucleic acid nanoparticles. Frontiers in immunology. 2023; 14; 1053550. [PubMed: 36798121].
|
|
